Mustafa R Bashir1, Steven R Breault2, Ryan Braun3, Richard K Do4, Rendon C Nelson2, Scott B Reeder5. 1. Department of Radiology, Duke University Medical Center, DUMC 3808, Durham, NC 27710. Electronic address: mustafa.bashir@duke.edu. 2. Department of Radiology, Duke University Medical Center, DUMC 3808, Durham, NC 27710. 3. Department of Radiology, Rush University Medical Center, Chicago, IL 60612. 4. Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065. 5. Department of Radiology, University of Wisconsin, Madison, WI 53792; Department of Medical Physics, University of Wisconsin, Madison, WI 53792; Department of Biomedical Engineering, University of Wisconsin, Madison, WI 53792; Department of Medicine, University of Wisconsin, Madison, WI 53792.
Abstract
RATIONALE AND OBJECTIVES: To evaluate clinical and imaging features associated with adequacy of the hepatocyte phase (HP) in gadoxetate disodium-enhanced liver magnetic resonance imaging (MRI) in patients without chronic liver disease (CLD). MATERIALS AND METHODS: This was a retrospective institutional review board-approved study of 97 patients who underwent liver MRI examinations with gadoxetate disodium and had no history of CLD. Available late dynamic and HP sequences (3-20 minutes postinjection) were independently analyzed by four radiologists for perceived image adequacy and level of biliary enhancement. Signal intensity ratios (SIRs) of liver/inferior vena cava (IVC), liver/spleen, and liver/muscle were measured. The Spearman ρ and receiver operating characteristic analyses were performed correlating various factors with HP adequacy. A rule for predicting HP adequacy was also derived and tested to determine whether overall examination time could be shortened. RESULTS: A visually adequate HP was observed in 12% of subjects by 10 minutes, 80% by 15 minutes, and 93% by 20 minutes. An SIRliver/IVC > 1.8 was the imaging feature that had the strongest correlation with an adequate HP (ρ = 0.813, P < .001), and was more predictive of adequacy of the HP than the time postinjection (ρ = 0.5, P < .001). The time at which an adequate HP was first observed did not correlate with any tested demographic or laboratory values. Stopping imaging when an SIRliver/IVC > 1.8 would have successfully reduced mean postcontrast time to 15:39 ± 4:02 from 20:00 (P < .001), although maintaining HP adequacy. CONCLUSIONS: Most patients without CLD undergoing gadoxetate-enhanced liver MRI achieve adequate HP at 20 minutes. However, a shorter postcontrast stopping time can be used in most patients.
RATIONALE AND OBJECTIVES: To evaluate clinical and imaging features associated with adequacy of the hepatocyte phase (HP) in gadoxetate disodium-enhanced liver magnetic resonance imaging (MRI) in patients without chronic liver disease (CLD). MATERIALS AND METHODS: This was a retrospective institutional review board-approved study of 97 patients who underwent liver MRI examinations with gadoxetate disodium and had no history of CLD. Available late dynamic and HP sequences (3-20 minutes postinjection) were independently analyzed by four radiologists for perceived image adequacy and level of biliary enhancement. Signal intensity ratios (SIRs) of liver/inferior vena cava (IVC), liver/spleen, and liver/muscle were measured. The Spearman ρ and receiver operating characteristic analyses were performed correlating various factors with HP adequacy. A rule for predicting HP adequacy was also derived and tested to determine whether overall examination time could be shortened. RESULTS: A visually adequate HP was observed in 12% of subjects by 10 minutes, 80% by 15 minutes, and 93% by 20 minutes. An SIRliver/IVC > 1.8 was the imaging feature that had the strongest correlation with an adequate HP (ρ = 0.813, P < .001), and was more predictive of adequacy of the HP than the time postinjection (ρ = 0.5, P < .001). The time at which an adequate HP was first observed did not correlate with any tested demographic or laboratory values. Stopping imaging when an SIRliver/IVC > 1.8 would have successfully reduced mean postcontrast time to 15:39 ± 4:02 from 20:00 (P < .001), although maintaining HP adequacy. CONCLUSIONS: Most patients without CLD undergoing gadoxetate-enhanced liver MRI achieve adequate HP at 20 minutes. However, a shorter postcontrast stopping time can be used in most patients.
Authors: Mustafa R Bashir; Rajan T Gupta; Matthew S Davenport; Brian C Allen; Tracy A Jaffe; Lisa M Ho; Daniel T Boll; Elmar M Merkle Journal: J Magn Reson Imaging Date: 2012-09-25 Impact factor: 4.813
Authors: Anum Aslam; Amita Kamath; Bradley Spieler; Mark Maschiocchi; Carl F Sabottke; Victoria Chernyak; Sara C Lewis Journal: Abdom Radiol (NY) Date: 2021-04-15
Authors: Michael A Ohliger; Cornelius von Morze; Irene Marco-Rius; Jeremy Gordon; Peder E Z Larson; Robert Bok; Hsin-Yu Chen; John Kurhanewicz; Daniel Vigneron Journal: Magn Reson Med Date: 2016-06-14 Impact factor: 4.668
Authors: Guilherme Moura Cunha; Kyle A Hasenstab; Atsushi Higaki; Kang Wang; Timo Delgado; Ryan L Brunsing; Alexandra Schlein; Armin Schwartzman; Albert Hsiao; Claude B Sirlin; Katie J Fowler Journal: Eur J Radiol Date: 2020-01-14 Impact factor: 3.528
Authors: Elmar M Merkle; Christoph J Zech; Carlo Bartolozzi; Mustafa R Bashir; Ahmed Ba-Ssalamah; Alexander Huppertz; Jeong Min Lee; Jens Ricke; Michiie Sakamoto; Claude B Sirlin; Sheng-Long Ye; Mengsu Zeng Journal: Eur Radiol Date: 2015-06-13 Impact factor: 5.315
Authors: Johannes Budjan; Philipp Riffel; Melissa M Ong; Stefan O Schoenberg; Ulrike I Attenberger; Daniel Hausmann Journal: BMC Med Imaging Date: 2017-05-09 Impact factor: 1.930